{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:38:34Z","timestamp":1792802314685,"version":"4.5.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astellas"},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Catabasis"},{"name":"Edgewise Therapeutics","id":[{"id":"https:\/\/ror.org\/03phcd550","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006591","name":"FibroGen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006591","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italfarmaco SpA"},{"name":"Marathon Pharmaceuticals"},{"DOI":"10.13039\/100031036","name":"NS Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031036","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Solid Biosciences","id":[{"id":"https:\/\/ror.org\/02h9td068","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Summit Therapeutics"},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005693","name":"Parent Project Muscular Dystrophy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005693","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Charley\u2019s Fund"},{"name":"CureDuchenne","id":[{"id":"https:\/\/ror.org\/054n08713","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fonds Spierzieke Kinderen"},{"name":"Avidity Biosciences"},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Entrada Therapeutics","id":[{"id":"https:\/\/ror.org\/02tcs0508","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Evaluations of treatment efficacy in Duchenne muscular dystrophy (DMD), a rare genetic disease that results in progressive muscle wasting, require an understanding of the \u2018meaningfulness\u2019 of changes in functional measures. We estimated the minimal detectable change (MDC) for selected motor function measures in ambulatory DMD, i.e., the minimal degree of measured change needed to be confident that true underlying change has occurred rather than transient variation or measurement error. MDC estimates were compared across multiple data sources, representing &gt;1000 DMD patients in clinical trials and real-world clinical practice settings. Included patients were ambulatory, aged \u22654 to &lt;18 years and receiving steroids. Minimal clinically important differences (MCIDs) for worsening were also estimated. Estimated MDC thresholds for &gt;80% confidence in true change were 2.8 units for the North Star Ambulatory Assessment (NSAA) total score, 1.3 seconds for the 4-stair climb (4SC) completion time, 0.36 stairs\/second for 4SC velocity and 36.3 meters for the 6-minute walk distance (6MWD). MDC estimates were similar across clinical trial and real-world data sources, and tended to be slightly larger than MCIDs for these measures. The identified thresholds can be used to inform endpoint definitions, or as benchmarks for monitoring individual changes in motor function in ambulatory DMD.<\/jats:p>","DOI":"10.1371\/journal.pone.0304984","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:39:59Z","timestamp":1720618799000},"page":"e0304984","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study"],"prefix":"10.1371","volume":"19","author":[{"given":"Francesco","family":"Muntoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-8962","authenticated-orcid":true,"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6517-646X","authenticated-orcid":true,"given":"Nicolae","family":"Done","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-5143","authenticated-orcid":true,"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0971-9789","authenticated-orcid":true,"given":"Brenda","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Vandenborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9046-3540","authenticated-orcid":true,"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda J. M.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Manzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima","family":"Dieye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-5263","authenticated-orcid":true,"given":"Susan J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PRO-DMD-01 study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Association Fran\u00e7aise contre les Myopathies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The UK NorthStar Clinical Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ImagingDMD investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"cTAP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"pone.0304984.ref001","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199681488.001.0001","volume-title":"Duchenne Muscular Dystrophy 4th Edition:","author":"A Emery","year":"2015"},{"issue":"1","key":"pone.0304984.ref002","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/cjn.2015.311","article-title":"A systematic review and meta-analysis on the epidemiology of the muscular dystrophies","volume":"43","author":"JK Mah","year":"2016","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"pone.0304984.ref003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy.","volume":"7","author":"D Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"pone.0304984.ref004","first-page":"574","article-title":"Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases","volume":"38","author":"CA Swinyard","year":"1957","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"pone.0304984.ref005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"E Scott","year":"2012","journal-title":"Physiother Res Int"},{"issue":"6","key":"pone.0304984.ref006","doi-asserted-by":"crossref","first-page":"e0232870","DOI":"10.1371\/journal.pone.0232870","article-title":"Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration.","volume":"15","author":"N Goemans","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"pone.0304984.ref007","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6\u2010minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"CM Mcdonald","year":"2013","journal-title":"Muscle & nerve"},{"issue":"2","key":"pone.0304984.ref008","first-page":"149","article-title":"The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials","volume":"87","author":"V Ricotti","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"pone.0304984.ref009","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","article-title":"Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls","volume":"32","author":"F Muntoni","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"pone.0304984.ref010","doi-asserted-by":"crossref","first-page":"e83400","DOI":"10.1371\/journal.pone.0083400","article-title":"6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes.","volume":"9","author":"M Pane","year":"2014","journal-title":"PLoS One."},{"issue":"9","key":"pone.0304984.ref011","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4155\/cli.11.113","article-title":"Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings.","volume":"1","author":"K Bushby","year":"2011","journal-title":"Clin Investig (Lond)."},{"issue":"4","key":"pone.0304984.ref012","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.21544","article-title":"The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy","volume":"41","author":"CM McDonald","year":"2010","journal-title":"Muscle Nerve"},{"issue":"7","key":"pone.0304984.ref013","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","article-title":"Reliability of the North Star Ambulatory Assessment in a multicentric setting","volume":"19","author":"ES Mazzone","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"pone.0304984.ref014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","article-title":"Understanding the minimum clinically important difference: a review of concepts and methods","volume":"7","author":"AG Copay","year":"2007","journal-title":"The Spine Journal"},{"issue":"1","key":"pone.0304984.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-4-54","article-title":"Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change.","volume":"4","author":"HC de Vet","year":"2006","journal-title":"Health and quality of life outcomes."},{"issue":"4","key":"pone.0304984.ref016","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status: ascertaining the minimal clinically important difference.","volume":"10","author":"R Jaeschke","year":"1989","journal-title":"Controlled clinical trials."},{"issue":"2","key":"pone.0304984.ref017","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"D Revicki","year":"2008","journal-title":"Journal of clinical epidemiology"},{"issue":"5","key":"pone.0304984.ref018","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0895-4356(03)00044-1","article-title":"Defining clinically meaningful change in health-related quality of life","volume":"56","author":"RD Crosby","year":"2003","journal-title":"Journal of clinical epidemiology"},{"issue":"7","key":"pone.0304984.ref019","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jclinepi.2009.12.015","article-title":"The minimal detectable change should not replace the minimal important difference","volume":"63","author":"HC de Vet","year":"2010","journal-title":"Journal of clinical epidemiology"},{"issue":"13","key":"pone.0304984.ref020","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jama.2014.13128","article-title":"Minimal clinically important difference: defining what really matters to patients","volume":"312","author":"AE McGlothlin","year":"2014","journal-title":"Jama"},{"issue":"11","key":"pone.0304984.ref021","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1044\/2018_JSLHR-S-17-0366","article-title":"Minimally detectable change and minimal clinically important difference of a decline in sentence intelligibility and speaking rate for individuals with amyotrophic lateral sclerosis","volume":"61","author":"KL Stipancic","year":"2018","journal-title":"J Speech Lang Hear Res"},{"issue":"11","key":"pone.0304984.ref022","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/dmcn.12220","article-title":"Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.","volume":"55","author":"AG Mayhew","year":"2013","journal-title":"Developmental Medicine & Child Neurology."},{"key":"pone.0304984.ref023","first-page":"5","article-title":"The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year.","author":"E Henricson","year":"2013","journal-title":"PLoS currents."},{"issue":"4","key":"pone.0304984.ref024","doi-asserted-by":"crossref","first-page":"e0283669","DOI":"10.1371\/journal.pone.0283669","article-title":"Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy.","volume":"18","author":"V Ayyar Gupta","year":"2023","journal-title":"PLoS One"},{"issue":"17","key":"pone.0304984.ref025","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy","volume":"89","author":"RG Victor","year":"2017","journal-title":"Neurology"},{"issue":"10101","key":"pone.0304984.ref026","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"CM McDonald","year":"2017","journal-title":"Lancet (London, England)."},{"issue":"4","key":"pone.0304984.ref027","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"K Bushby","year":"2014","journal-title":"Muscle Nerve"},{"issue":"1","key":"pone.0304984.ref028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy","volume":"28","author":"N Goemans","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"pone.0304984.ref029","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.","volume":"13","author":"T Voit","year":"2014","journal-title":"Lancet Neurol"},{"issue":"20","key":"pone.0304984.ref030","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"RC Griggs","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"pone.0304984.ref031","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1469-8749.2011.03939.x","article-title":"Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.","volume":"53","author":"A Mayhew","year":"2011","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"pone.0304984.ref032","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/pst.1787","article-title":"Estimating the reliability of repeatedly measured endpoints based on linear mixed\u2010effects models. A tutorial.","volume":"15","author":"W Van der Elst","year":"2016","journal-title":"Pharmaceutical statistics."},{"issue":"5","key":"pone.0304984.ref033","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.","volume":"41","author":"GR Norman","year":"2003","journal-title":"Med Care."},{"key":"pone.0304984.ref034","author":"U.S. Food and Drug Administration","year":"2019","journal-title":"Incorporating clinical outcome assessments into endpoints for regulatory decision-making"},{"issue":"10","key":"pone.0304984.ref035","doi-asserted-by":"crossref","first-page":"e0164684","DOI":"10.1371\/journal.pone.0164684","article-title":"Collaborative Trajectory Analysis Project. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.","volume":"11","author":"N Goemans","year":"2016","journal-title":"PLoS One."},{"issue":"6","key":"pone.0304984.ref036","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3233\/JND-210646","article-title":"The minimal clinical important difference (MCID) in annual rate of change of timed function tests in boys with DMD.","volume":"8","author":"T Duong","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"pone.0304984.ref037","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1015291021312","article-title":"Assessing health status and quality-of-life instruments: attributes and review criteria.","volume":"11","author":"N Aaronson","year":"2002","journal-title":"Qual Life Res"},{"issue":"1","key":"pone.0304984.ref038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1477-7525-4-89","article-title":"Assessing responsiveness of generic and specific health related quality of life measures in heart failure","volume":"4","author":"DT Eurich","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"key":"pone.0304984.ref039","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.nmd.2020.08.283","article-title":"DMD\u2013THERAPY.","volume":"30","author":"M Eagle","year":"2020","journal-title":"Neuromuscular Disorders"},{"key":"pone.0304984.ref040","doi-asserted-by":"crossref","first-page":"m1714","DOI":"10.1136\/bmj.m1714","article-title":"Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study","volume":"369","author":"T Devji","year":"2020","journal-title":"BMJ"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:41:07Z","timestamp":1720618867000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304984"}},"subtitle":[],"editor":[{"given":"Atsushi","family":"Asakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304984","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]}}}